What is the recommended dosing of zinc L‑carnosine (polaprezinc) for gastric ulcer healing and for liver‑related gut barrier support, and are there safety considerations such as renal impairment?

Zinc L-Carnosine Dosing and Safety

For gastric ulcer healing, use polaprezinc 150 mg daily (75 mg twice daily), and for patients with severe zinc deficiency or liver-related gut barrier dysfunction, consider 300 mg daily (150 mg twice daily) if baseline serum zinc is below 70 µg/dL. There are no specific renal dose adjustments established in the literature, but caution is warranted given zinc's renal excretion.

Dosing by Indication

Gastric Ulcer Healing

• Standard dose: 150 mg daily (divided as 75 mg twice daily)
• This dosing accelerates gastric ulcer healing through IGF-1 upregulation and heat shock protein 72 induction 1
• The compound demonstrates preferential binding to damaged mucosa, releasing zinc locally via ligand exchange 2

Zinc Deficiency Correction

The optimal dose depends on baseline serum zinc concentration 3:

• Baseline zinc ≥70 µg/dL: Use 150 mg daily
• Baseline zinc <70 µg/dL: Use 300 mg daily for more aggressive repletion
• A clear dose-response relationship exists, with higher doses producing greater increases in serum zinc (mean increase of 9.08 µg/dL above placebo across all doses) 3

Gut Barrier Protection in Liver Disease

• Dose range: 90-300 mg daily (30-100 mg three times daily)
• In portal hypertensive gastropathy with cirrhosis, zinc L-carnosine (30-300 mg/kg in rat models, translating to approximately 150-300 mg daily in humans) protected gastric mucosa through hsp72 induction 4
• The compound stabilizes small bowel integrity and prevents NSAID-induced increases in gut permeability at 75 mg daily 5

Mechanism-Based Rationale

Zinc L-carnosine works through multiple complementary pathways:

• Direct mucosal cytoprotection via antioxidative effects and membrane stabilization
• Stimulation of epithelial cell migration and proliferation (threefold increase at optimal concentrations)
• Cytokine modulation and anti-inflammatory action
• Preferential accumulation at sites of mucosal damage 5, 2

Safety Considerations

Gastrointestinal Tolerability

A dose-dependent relationship exists between zinc L-carnosine dose and gastrointestinal adverse events 3. All doses (75 mg, 150 mg, 300 mg) were tolerable in clinical trials, but higher doses carry increased risk of GI upset.

Renal Impairment

Critical caveat: While no specific renal dosing guidelines exist for zinc L-carnosine, zinc is substantially excreted by the kidney. In patients with impaired renal function:

• Start at the lower end of the dosing range (75-150 mg daily)
• Monitor serum zinc levels to avoid accumulation
• Consider dose reduction if GI symptoms emerge

Characterization Concerns

A 2026 EFSA safety assessment raised concerns about incomplete characterization of zinc L-carnosine, noting the material's insolubility at neutral pH and uncertainty about nanoparticle content 6. However, this assessment focused on novel food applications, and decades of clinical use in Japan and other countries at the doses recommended above have demonstrated acceptable safety profiles.

Populations to Avoid

• Pregnant and lactating women (insufficient safety data)
• Children under 12 years (limited pediatric data)

Practical Implementation

For gastric ulcer patients: Start 75 mg twice daily with meals, continue for 8-12 weeks minimum based on healing response 1, 7

For liver disease with gut barrier dysfunction: Use 75-150 mg twice daily, particularly when portal hypertensive gastropathy is present 4

For zinc deficiency: Check baseline serum zinc, then dose accordingly (150 mg if ≥70 µg/dL, 300 mg if <70 µg/dL), reassess levels after 12 weeks 3

Monitoring: In patients with renal impairment or those on prolonged therapy, periodic serum zinc monitoring helps prevent both deficiency and excess.